A NEW head-to-head study of tirzepatide (Mounjaro) versus semaglutide (Ozempic/Wegovy) for weight loss in people living with obesity, but not diabetes, has found that Mounjaro resulted in greater weight loss over 72 weeks than Wegovy.
The study, which was sponsored by Mounjaro manufacturer Eli Lilly, was presented at this year's European Congress on Obesity and published in NEJM.
It included 750 patients who were randomised to receive either Mounjaro or Wegovy, with those on Mounjaro achieving an average weight loss of 20.2%, compared with 13.7% average weight loss for Wegovy.
In other results, 65% of participants treated with Mounjaro lost at least 15% of their body weight compared with 40% of those on Wegovy, and attained an average waist circumference reduction of 18cm compared with 13cm for Wegovy.
Adverse events reported during the trial were similar for both medications and related primarily to gastrointestinal symptoms, which were generally mild to moderate in severity.
Around 6-8% of participants dropped out due to side effects.
While both drugs are highly effective obesity management medications, this new study is the first to test, in a head-to-head trial, their efficacy and safety in adults with obesity but without type 2 diabetes.
"Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before," said study lead, Professor Louis Aronne.
"The head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management," he added.
Read the study HERE. KB
The above article was sent to subscribers in Pharmacy Daily's issue from 13 May 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 May 25
